Clinical trials / NCT06196034
Recruiting

Genetic Association With Various Severities, Phenotypes and Endotypes of Asthma.

There is limited information on genetics associated with asthma in Chinese. An earlier meta-analysis found that ADAM33, FcεRIb, RANTES, TNF-a, ACE, b2-AR, IL-4R and IL-13 genes could be proposed as asthma susceptible genes in the Chinese population. However, given the limited number of studies, more data are required to validate these associations. Future research must address key issues such as the broad clinical variability of asthma and the underrepresentation of populations of non-European heritage…

ClinicalTrials.gov IDNCT06196034
PhaseNot Applicable
Enrollment2000
SponsorChinese University of Hong Kong
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Asthma

About this study

There is limited information on genetics associated with asthma in Chinese. An earlier meta-analysis found that ADAM33, FcεRIb, RANTES, TNF-a, ACE, b2-AR, IL-4R and IL-13 genes could be proposed as asthma susceptible genes in the Chinese population. However, given the limited number of studies, more data are required to validate these associations. Future research must address key issues such as the broad clinical variability of asthma and the underrepresentation of populations of non-European heritage. Endotype-specific SNPs and unique biological insights may be obtained by conducting GWAS/EWAS on homogeneous populations of more therapy-resistant T2-low, adult-onset, obesity-associated asthma or asthma with particular co-morbidities. The primary objective is to investigate the association between genetic polymorphisms and various severities of asthma.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * • All patients with confirmed diagnosis of asthma (defined as those with a consistent history and prior documented evidence of variable airflow obstruction, with evidence of an increase in FEV1 greater than 12% or 400 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable) 12 * Able to sign written informed consent form to participate in the study. Exclusion Criteria: * • Patients currently with acute exacerbation of asthma by GINA guideline. (For subjects with asthma exacerbation, they can join the study after 6 weeks post recovery from the exacerbation.) * Patients with respiratory diseases that can show similar symptoms to chronic airway diseases such as bronchiectasis, tuberculosis(TB)-destroyed lung parenchyma, endobronchial TB, and lung cancer, or those who have history of these diseases based on physician's judgment. * Patients currently diagnosed with pneumonia and acute bronchitis. For control subject: the inclusion will be having no clinical diagnosis of asthma.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.